Riskpilot← Back to searchSign inGet full accessConsult & PapLex Oy
OYActiveY-tunnus 2578790-3Turuntie 29-5Accounting, bookkeeping and auditing activities; tax consultancy · NACE 6920Est. 2013— employees
Revenue 2025
EUR 136K
+12% vs 2024
EBITDA margin
7.6%
+372% vs 2024
Equity ratio
54.7%
Financial strength
Net profit 2025
EUR 10K
+365% vs 2024
| Revenue | EUR 136K | +12% |
| EBITDA | EUR 10K | +372% |
| Net profit | EUR 10K | +365% |
| Total assets | EUR 19K | +132% |
| Equity | EUR 10K | +11608% |
| Employees | — | — |
Legal name
Consult & PapLex Oy
Y-tunnus number
2578790-3
Legal form
Osakeyhtiö
NACE code
6920 · Accounting, bookkeeping and auditing activities; tax consultancy
Founded
23. lokakuuta 2013
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on yrityksen liikkeenjohdon sekä kaikki lailla sallittu liiketoiminta.
Address
Turuntie 29-5
Phone
+358407611181
Email
consult.paplex@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 100 | 123 | 126 | 122 | 136 |
| Staff expenses | −89 | −101 | −108 | −109 | −107 |
| EBITDA | −10 | −4 | −5 | −4 | 10 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −10 | −4 | −6 | −4 | 10 |
| Net financials | −0 | −0 | 0 | −0 | 0 |
| Profit before tax | −11 | −4 | −6 | −4 | 10 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −11 | −4 | −6 | −4 | 10 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 21 | 17 | 11 | 8 | 19 |
| Equity | 13 | 9 | 4 | 0 | 10 |
| Long-term debt | — | — | 0 | 0 | 0 |
| Short-term debt | 7 | 8 | 756 | 8 | 9 |
| Total debt | 7 | 8 | 8 | 8 | 9 |
EBITDA margin
7.6%
This company
15.8%
Market median
-52% vs market
20212025
Equity ratio
54.7%
This company
38.2%
Market median
+43% vs market
20212025
Return on equity
99.1%
This company
18.4%
Market median
+439% vs market
20212025
Net profit margin
7.5%
This company
8.1%
Market median
-7% vs market
20212025
Asset turnover
7.20×
This company
1.12×
Market median
+543% vs market
20212025
Debt / equity
0.83×
This company
0.62×
Market median
+34% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SB Person with significant control | Person with significant control | 2019 |
| Former (1) | ||
LL Deputy Member | Deputy Member | 2017 – 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2019 | |
| Former (1) | ||
| Board of Directors | 2017 – 2019 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Consult & PapLex Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sergo Belov | Person with significant control | 0 companies |
| Linda Laine Vogelainen | Deputy Member | 0 companies |
| Mikael Vogelainen | Board of Directors | 0 companies |
| Algi Belov | Board of Directors | 0 companies |